943d A Phase 2/3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT SC
W. Sandborn, P. J. Rutgeerts, Peter G. Gibson(University Gastroenterology), Brian G. Feagan(Western University), H. Zhang, J. Collins, G Järnerot, J F Colombel(Icahn School of Medicine at Mount Sinai), Walter Reinisch(Medical University of Vienna), Richard Strauß(Hennepin County Medical Center), Jewel Johanns(Johnson & Johnson (United States)), C. W. Marano
Cited by 27
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations
|American Journal of Respiratory and Critical Care Medicine|2009|1.9k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k